The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium

Biomaterials

Volumn 35, Issue 33, 2014, Pages 9199-9207

  Araújo, Francisca ^a,b,c   Shrestha, Neha ^c   Shahbazi, Mohammed Ali ^c   Fonte, Pedro ^b,d   Mäkilä, Ermei M ^c,e   Salonen, Jarno J ^e   Hirvonen, Jouni T ^c   Granja, Pedro L ^a,b   Santos, Hélder A ^c   Sarmento, Bruno ^a,d  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Chitosan; Diabetes; Glucagon like peptide 1; Nanoparticles; Oral delivery systems; Triple co culture

Indexed keywords

BIOCHEMISTRY; BODY FLUIDS; CHITOSAN; COPOLYMERS; LOADING; MEDICAL PROBLEMS; NANOPARTICLES; PEPTIDES; POROUS SILICON;

ASSOCIATION EFFICIENCY; COCULTURE; GASTROINTESTINAL TRACT; GLUCAGON LIKE PEPTIDE-1; ORAL DELIVERY; POLY LACTIDE-CO-GLYCOLIDE; SOLID LIPID NANOPARTICLE (SLN); TYPE 2 DIABETES MELLITUS;

NANOSYSTEMS;

BIOMATERIAL; CHITOSAN; GLUCAGON LIKE PEPTIDE 1; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; SILICON; SOLID LIPID NANOPARTICLE; WITEPSOL E 85; DRUG CARRIER;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE MUCOSA; MUCUS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TRANSPORT; CACO 2 CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HT 29 CELL LINE; METABOLISM; MUCOSA; NANOTECHNOLOGY; PARTICLE SIZE; PERMEABILITY; POROSITY; PROCEDURES;

BIOCOMPATIBLE MATERIALS; CACO-2 CELLS; CELL SURVIVAL; CHITOSAN; DRUG CARRIERS; GLUCAGON-LIKE PEPTIDE 1; HT29 CELLS; HUMANS; INTESTINAL MUCOSA; MUCOUS MEMBRANE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PERMEABILITY; POLYGLACTIN 910; POROSITY; SILICON;

EID: 84906788144     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.026     Document Type: Article

References (54)

1. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharmacol 2013, 35:159-172.
2. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013, 17:819-837.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
4. Tahrani A.A., Piya M.K., Kennedy A., Barnett A.H. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010, 125:328-361.
5. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. JClin Endocrinol Metab 2002, 87:1239-1246.
6. Rekha M.R., Sharma C.P. Oral delivery of therapeutic protein/peptide for diabetes-future perspectives. Int J Pharm 2013, 440:48-62.
7. Araújo F., Fonte P., Santos H.A., Sarmento B. Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?. JDiabetes Sci Technol 2012, 6:1486-1497.
8. Gupta S., Jain A., Chakraborty M., Sahni J.K., Ali J., Dang S. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv 2013, 20:237-246.
9. Joseph J.W., Kalitsky J., St-Pierre S., Brubaker P.L. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia 2000, 43:1319-1328.
10. Chae S.Y., Jin C.H., Shin H.J., Youn Y.S., Lee S., Lee K.C. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem 2008, 19:334-341.
11. Nguyen H.N., Wey S.P., Juang J.H., Sonaje K., Ho Y.C., Chuang E.Y., et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion invivo. Biomaterials 2011, 32:2673-2682.
12. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. JControl Release 2012, 161:505-522.
13. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Mäkilä E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
14. Sarmento B., Martins S., Ferreira D., Souto E.B. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2007, 2:743-749.
15. Shahbazi M.A., Santos H.A. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 2013, 14:28-56.
16. Salonen J., Kaukonen A.M., Hirvonen J., Lehto V.P. Mesoporous silicon in drug delivery applications. JPharm Sci 2008, 97:632-653.
17. Fredenberg S., Wahlgren M., Reslow M., Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm 2011, 415:34-52.
18. Zhang X., Sun M., Zheng A., Cao D., Bi Y., Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 2012, 45:632-638.
19. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012, 64:557-570.
20. Sarmento B., Ribeiro A., Veiga F., Ferreira D., Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 2007, 8:3054-3060.
21. Andrade F., Antunes F., Nascimento A.V., da Silva S.B., das Neves J., Ferreira D., et al. Chitosan formulations as carriers for therapeutic proteins. Curr Drug Discov Technol 2011, 8:157-172.
22. Shahbazi M.A., Hamidi M. The impact of preparation parameters on typical attributes of chitosan-heparin nanohydrogels: particle size, loading efficiency, and drug release. Drug Dev Ind Pharm 2013, 39:1774-1782.
23. Zhang N., Ping Q., Huang G., Xu W., Cheng Y., Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006, 327:153-159.
24. García-Fuentes M., Torres D., Alonso M.J. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B Biointerfaces 2003, 27:159-168.
25. Shahbazi M.A., Almeida P.A., Mäkilä E.M., Kaasalainen M.H., Salonen J.J., Hirvonen J.T., et al. Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. Biomaterials 2014, 35:7488-7500.
26. Shrestha N., Shahbazi M.A., Araújo F., Zhang H., Mäkilä E., Kauppila J., et al. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials 2014, 35:7172-7179.
27. Li X., Guo S., Zhu C., Zhu Q., Gan Y., Rantanen J., et al. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 2013, 34:9678-9687.
28. Sarmento B., Ribeiro A., Veiga F., Ferreira D. Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf B Biointerfaces 2006, 53:193-202.
29. Bimbo L.M., Mäkilä E., Raula J., Laaksonen T., Laaksonen P., Strommer K., et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011, 32:9089-9099.
30. Araújo F., Sarmento B. Towards the characterization of an invitro triple co-culture intestine cell model for permeability studies. Int J Pharm 2013, 458:128-134.
31. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
32. Caldorera-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010, 7:479-495.
33. Wang Y., Li P., Kong L. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech 2013, 14:585-592.
34. Chen M.C., Mi F.L., Liao Z.X., Hsiao C.W., Sonaje K., Chung M.F., et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013, 65:865-879.
35. Emami J., Hamishehkar H., Najafabadi A.R., Gilani K., Minaiyan M., Mahdavi H., et al. Anovel approach to prepare insulin-loaded poly(lactic-co-glycolic acid) microcapsules and the protein stability study. JPharm Sci 2009, 98:1712-1731.
36. Fonte P., Nogueira T., Gehm C., Ferreira D., Sarmento B. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res 2011, 1:299-308.
37. Cohen-Sela E., Chorny M., Koroukhov N., Danenberg H.D., Golomb G. Anew double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. JControl Release 2009, 133:90-95.
38. Liu D., Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz-Blanco B., et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. JControl Release 2013, 170:268-278.
39. Kovalainen M., Mönkäre J., Mäkilä E., Salonen J., Lehto V.P., Herzig K.H., et al. Mesoporous silicon (PSi) for sustained peptide delivery: effect of PSi microparticle surface chemistry on peptide YY3-36 release. Pharm Res 2012, 29:837-846.
40. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007, 59:478-490.
41. Antunes F., Andrade F., Araujo F., Ferreira D., Sarmento B. Establishment of a triple co-culture invitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 2013, 83:427-435.
42. Sarmento B., Andrade F., da Silva S.B., Rodrigues F., das Neves J., Ferreira D. Cell-based invitro models for predicting drug permeability. Expert Opin Drug Metab Toxicol 2012, 8:607-621.
43. Shah S., Shah P., Todkar J., Gagner M., Sonar S., Solav S. Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis 2010, 6:152-157.
44. Huotari A., Xu W., Monkare J., Kovalainen M., Herzig K.H., Lehto V.P., et al. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity. Int J Pharm 2013, 454:67-73.
45. Martins S., Sarmento B., Souto E.B., Ferreira D.C. Insulin-loaded alginate microspheres for oral delivery - effect of polysaccharide reinforcement on physicochemical properties and release profile. Carbohydr Polym 2007, 69:725-731.
46. Li J., Jiang G., Ding F. The effect of pH on the polymer degradation and drug release from PLGA-mPEG microparticles. JApp Polym Sci 2008, 109:475-482.
47. Buske J., Konig C., Bassarab S., Lamprecht A., Muhlau S., Wagner K.G. Influence of PEG in PEG-PLGA microspheres on particle properties and protein release. Eur J Pharm Biopharm 2012, 81:57-63.
48. Giteau A., Venier-Julienne M.C., Aubert-Pouessel A., Benoit J.P. How to achieve sustained and complete protein release from PLGA-based microparticles?. Int J Pharm 2008, 350:14-26.
49. Chakravarthi S.S., Robinson D.H. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 2011, 409:111-120.
50. Garcia-Fuentes M., Torres D., Alonso M.J. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm 2005, 296:122-132.
51. des Rieux A., Ragnarsson E.G., Gullberg E., Preat V., Schneider Y.J., Artursson P. Transport of nanoparticles across an invitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci 2005, 25:455-465.
52. Huhn D., Kantner K., Geidel C., Brandholt S., De Cock I., Soenen S.J., et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano 2013, 7:3253-3263.
53. Lee S.Y., Huh M.S., Lee S., Lee S.J., Chung H., Park J.H., et al. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. JControl Release 2010, 141:339-346.
54. Fuller J.E., Zugates G.T., Ferreira L.S., Ow H.S., Nguyen N.N., Wiesner U.B., et al. Intracellular delivery of core-shell fluorescent silica nanoparticles. Biomaterials 2008, 29:1526-1532.